SGLT2 inhibitors in heart failure
Use of SGLT2 inhibitors such as dapagliflozin and empagliflozin across heart failure types.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 58, 74, 76, 73, 83.
New guidelines and consensus this year
- Pharmacological treatment strategies to prevent heart failure across the cardiovascular-kidney-metabolic spectrum: an EJHF Expert Consensus StatementEur J Heart Fail2026 Oct 1
- ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic SyndromeJ Am Soc Nephrol2026 Oct 1
- Prevention of Heart Failure in Women: An Expert Consensus Statement on Sex-Specific Risk FactorsEur J Heart Fail2026 Jul 3
- Kidney disease and heart failure: recent advances and current challenges: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceKidney Int2026 Jun
- Ibero-American position statement on therapeutic recommendations for the preventive management of cardiovascular complications in latin-American patients with type 2 diabetes mellitus: consensus of the prevention council of the inter-American society of cardiology (SIAC-PREVENT)Diabetol Metab Syndr2026 Apr 12
All papers from the last 12 months
1,322 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Efficacy and mechanistic insights of dapagliflozin in hypertension managementClin Exp Hypertens2026 Dec 31PMID 42826222Review
- Multisystem effects of sodium-glucose cotransporter-2 inhibitors beyond glycaemic control: an umbrella review of systematic reviews and meta-analysesJ Diabetes Metab Disord2026 DecPMID 42856812Review
- Real-world prescribing patterns of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes with various ASCVD subtypes from a large tertiary referral centerAm J Prev Cardiol2026 DecPMID 42827863
- From evidence to delivery: Optimising SGLT2 inhibitor therapy in heart failureInt J Cardiol2026 Dec 1PMID 42679960
- Efficacy and safety of SGLT2 inhibitors in elderly patients with type 2 diabetesAnn Med2026 DecPMID 42439602
- Clinical events and healthcare costs of dapagliflozin in adults with cardiovascular-kidney-metabolic syndrome in Spain: a cost-offset analysisJ Med Econ2026 DecPMID 42343656
- Bibliometric analysis of sacubitril/valsartan in the management of chronic kidney disease (2013-2025)Ren Fail2026 DecPMID 41943607Review
- Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m(2): A Target Trial EmulationDiabetes Obes Metab2026 NovPMID 42642357
- Sudden cardiac death in chronic kidney disease and dialysis: From descriptive epidemiology to mechanism-driven preventionJ Intern Med2026 NovPMID 42625486Review
- From pathobiology to prescribing in obesity-driven HFpEF: A systematic review and practical therapeutic frameworkCurr Probl Cardiol2026 NovPMID 42586458Systematic review
More cardiology trends
All specialties →HFpEF
Heart failure with preserved ejection fraction.
AI-enabled ECG
Artificial intelligence applied to electrocardiograms to detect or predict disease.
TAVR / TAVI
Transcatheter aortic valve replacement for aortic stenosis.
Cardiac myosin inhibitors
Drugs such as mavacamten and aficamten for hypertrophic cardiomyopathy.
Remote cardiac rehabilitation
Cardiac rehabilitation delivered at home or through digital tools.
Key point: Exercise-based telerehabilitation probably improves cardiorespiratory fitness in adults with CVD but provides no convincing evidence of an antihypertensive effect.
Inclisiran
An siRNA drug that lowers LDL cholesterol by reducing PCSK9 production in the liver.
Key point: Inclisiran achieves similar LDL-C reductions with biannual dosing, potentially improving adherence, though cardiovascular outcome data are pending.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
(SGLT2[tiab] OR "sodium-glucose cotransporter 2"[tiab] OR dapagliflozin[tiab] OR empagliflozin[tiab]) AND "heart failure"[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.